BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sonoyama H, Kawashima K, Ishihara S, Kotani S, Fukuba N, Oka A, Kusunoki R, Tada Y, Mishima Y, Oshima N, Moriyama I, Yuki T, Onishi K, Kinoshita Y. Capabilities of fecal calprotectin and blood biomarkers as surrogate endoscopic markers according to ulcerative colitis disease type. J Clin Biochem Nutr 2019;64:265-70. [PMID: 31138962 DOI: 10.3164/jcbn.18-92] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Ishida N, Higuchi T, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis. Sci Rep 2021;11:12431. [PMID: 34127687 DOI: 10.1038/s41598-021-90558-z] [Reference Citation Analysis]
2 Wang Y, Li C, Wang W, Wang J, Li J, Qian S, Cai C, Liu Y. Serum Albumin to Globulin Ratio is Associated with the Presence and Severity of Inflammatory Bowel Disease. JIR 2022;Volume 15:1907-20. [DOI: 10.2147/jir.s347161] [Reference Citation Analysis]
3 Eckard AR, Hughes HY, Hagood NL, O'Riordan MA, Labbato D, Kosco JC, Scott SE, McComsey GA. Fecal Calprotectin Is Elevated in HIV and Related to Systemic Inflammation. J Acquir Immune Defic Syndr 2021;86:231-9. [PMID: 33065582 DOI: 10.1097/QAI.0000000000002538] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 D'Amico F, Nancey S, Danese S, Peyrin-Biroulet L. A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities. J Crohns Colitis 2021;15:152-61. [PMID: 32392336 DOI: 10.1093/ecco-jcc/jjaa093] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
5 Cha N, Oshima N, Kishimoto K, Kotani S, Okimoto E, Yazaki T, Sonoyama H, Oka A, Mishima Y, Shibagaki K, Tobita H, Kawashima K, Ishimura N, Ishihara S. Long-lasting renal dysfunction following tacrolimus induction therapy in ulcerative colitis patients. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-139] [Reference Citation Analysis]
6 Wagatsuma K, Yokoyama Y, Nakase H. Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life (Basel) 2021;11:1375. [PMID: 34947906 DOI: 10.3390/life11121375] [Reference Citation Analysis]
7 Sakuraba A, Nemoto N, Hibi N, Ozaki R, Tokunaga S, Kikuchi O, Minowa S, Mitsui T, Miura M, Saito D, Hayashida M, Miyoshi J, Matsuura M, Yoneyama M, Ohnishi H, Hisamatsu T. Extent of disease affects the usefulness of fecal biomarkers in ulcerative colitis. BMC Gastroenterol 2021;21:197. [PMID: 33933033 DOI: 10.1186/s12876-021-01788-4] [Reference Citation Analysis]
8 Lin H, Bai Z, Wu Q, Chu G, Zhang Y, Guo X, Qi X. Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study. Front Public Health 2022;10:851295. [PMID: 35359771 DOI: 10.3389/fpubh.2022.851295] [Reference Citation Analysis]
9 Kyle BD, Agbor TA, Sharif S, Chauhan U, Marshall J, Halder SLS, Ip S, Khan WI. Fecal Calprotectin, CRP and Leucocytes in IBD Patients: Comparison of Biomarkers With Biopsy Results. J Can Assoc Gastroenterol 2021;4:84-90. [PMID: 33855266 DOI: 10.1093/jcag/gwaa009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]